Literature DB >> 23036774

Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma.

Yasser G Abd El-Hafez1, Hosna M Moustafa, Haytham F Khalil, Chun-Ta Liao, Tzu-Chen Yen.   

Abstract

OBJECTIVES: We sought to determine potential prognostic value of total lesion glycolysis (TLG) calculated from combined positron emission tomography/computed tomography (PET/CT) in patients with oral cavity squamous cell carcinoma (OSCC).
MATERIALS AND METHODS: We prospectively studied 126 patients with OSCC who underwent PET/CT before definitive treatment by radical surgery. The metabolic tumor volume (MTV) was calculated for the primary tumor according to an absolute standardized uptake value (SUV) of 3. TLG was calculated as MTV × the average SUV. The nodal SUVmax was also recorded. The median value of SUVmax and TLG were used to divide the patients into two categories (high and low). Patients were followed up until death or for at least 24 months from their surgery. Disease-free (DFS) and disease-specific survivals (DSS) were the main outcome measures.
RESULTS: The median TLG of the primary tumor ((T)TLG) was 71.4, and the median nodal SUVmax ((N)SUV) was 7.5. Patients with high (T)TLG (≥ median) had a 2-year DFS of 52% whereas the DFS was 74% for those with a low (T)TLG (P=0.007); the 2-year-DSS rates were 53% vs. 84%, respectively (P<0.001). Similarly, patients with high (N)SUVmax (≥ median) had a 2-year DFS of 42% vs. 70% for patients with a low (N)SUVmax (P=0.001); the 2-year-DSS rates were 39% vs. 78%, respectively (P<0.001). In multivariate analyses, (T)TLG, (N)SUVmax, and pathological nodal status were independent prognostic factors for the 2-year DSS. A 3-point prognostic scoring system was formulated based on the presence or absence of the independent factors. Patients with positive neck nodes, high (N)SUVmax, and high (T)TLG (score 3) had a 32-fold higher risk of cancer death compared with those lacking such risk factors (2-year-DSS=26% vs. 97%, P<0.001).
CONCLUSION: Primary tumor TLG is an independent prognostic factor for cancer control and survival in patients with OSCC. A prognostic scoring system that includes primary tumor TLG, nodal SUVmax, and pathological neck status may be useful for risk stratification in this group of patients.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23036774     DOI: 10.1016/j.oraloncology.2012.09.005

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  21 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

2.  Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.

Authors:  Esther Mena; Mehdi Taghipour; Sara Sheikhbahaei; Abhinav K Jha; Arman Rahmim; Lilja Solnes; Rathan M Subramaniam
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

3.  18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?

Authors:  A Tuba Kendi; Amanda Corey; Kelly R Magliocca; Dana C Nickleach; James Galt; Jeffrey M Switchenko; Mark W El-Deiry; J Trad Wadsworth; Patricia A Hudgins; Nabil F Saba; David M Schuster
Journal:  Eur J Radiol       Date:  2015-03-14       Impact factor: 3.528

Review 4.  The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.

Authors:  Giovanni Cammaroto; Natale Quartuccio; Alessandro Sindoni; Francesca Di Mauro; Federico Caobelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

Review 5.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

6.  Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics.

Authors:  Michael R Folkert; Jeremy Setton; Aditya P Apte; Milan Grkovski; Robert J Young; Heiko Schöder; Wade L Thorstad; Nancy Y Lee; Joseph O Deasy; Jung Hun Oh
Journal:  Phys Med Biol       Date:  2017-06-12       Impact factor: 3.609

7.  Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.

Authors:  Takuya Toyonaga; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Osamu Manabe; Shiro Watanabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Naoya Hattori; Tohru Shiga; Yuji Kuge; Shinya Tanaka; Yoichi M Ito; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-18       Impact factor: 9.236

8.  Impact of image reconstruction methods on quantitative accuracy and variability of FDG-PET volumetric and textural measures in solid tumors.

Authors:  Ali Ketabi; Pardis Ghafarian; Mohammad Amin Mosleh-Shirazi; Seyed Rabi Mahdavi; Arman Rahmim; Mohammad Reza Ay
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

9.  Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer.

Authors:  Hidenori Suzuki; Masami Nishio; Hayao Nakanishi; Nobuhiro Hanai; Hitoshi Hirakawa; Takeshi Kodaira; Tsuneo Tamaki; Yasuhisa Hasegawa
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

10.  A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction.

Authors:  Arman Rahmim; C Ross Schmidtlein; Andrew Jackson; Sara Sheikhbahaei; Charles Marcus; Saeed Ashrafinia; Madjid Soltani; Rathan M Subramaniam
Journal:  Phys Med Biol       Date:  2015-12-07       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.